US70465T1079
US70465T1079
PDS Biotechnology Corporation
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 50/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±107.0% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.
Beta (Market Relation)
1.17x
Above averageVolatility (5Y p.a.)
107.0% p.a.
5-Year HorizonMax Drawdown (5Y)
-98.6%
5-Year HorizonSharpe Ratio
-0.40
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
Volatility Expansion (3Y > 5Y) High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +2% |
| 3 Years | 115.6% | -97.0% | -0.37 | -40.4% |
| 5 Years | 107.0% | -98.6% | -0.4 | -40.4% |
| 10 Years | 110.0% | -99.9% | -0.4 | -41.6% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (115.6%) is noticeably higher than the 5Y average (107.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (107.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -99.9% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
0.13